Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801368 | 0.78 | RET (0.33) | MEN1KMT2ARET | |
| SCHEMBL21178876 | 0.77 | RET (0.40) | MEN1KMT2AEGFRRET | |
| SCHEMBL21801345 | 0.76 | L3MBTL1 (0.36) | L3MBTL1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL22037128 | 0.71 | MEN1 (0.41) | MEN1KMT2ARET | |
| SCHEMBL21801527 | 0.71 | — | — | |
| SCHEMBL21178731 | 0.70 | ADK (0.31) | — | |
| SCHEMBL12590776 | 0.66 | CYP1A2 (0.44) | L3MBTL1CYP4F2CYP4A11TSHRTNF | |
| SCHEMBL18341927 | 0.66 | RET (0.37) | MEN1KMT2ARET | |
| SCHEMBL21179013 | 0.65 | ATM (0.40) | LMNAMAPTTSHRKMT2ARXFP1 | |
| SCHEMBL12844463 | 0.65 | L3MBTL1 (0.45) | L3MBTL1CYP4F2CYP4A11LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3849986-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020055672-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | L3MBTL1 1737/4885CYP4F2 2243/4885CYP4A11 2048/4885 |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | RET, ROR1, FRK | L3MBTL1 1737/4885CYP4F2 2243/4885CYP4A11 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.